Form 4 for RGNX REGENXBIO Inc.
Accepted 2024-07-03 00:00:00 ET · period of report 2024-07-01 · accession 0001562180-24-005566 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-07-03 | 2024-07-01 | RGNX | KARABELAS ARGERIS N | Dir | S - Sale+OE | $11.27 | -10.0K | 11.3K | -47% | -$112.7K |
| DT | 2024-07-03 | 2024-07-01 | RGNX | KARABELAS ARGERIS N | Dir | M - OptEx | $3.76 | +10.0K | 21.3K | +89% | +$37.6K |
| DT | 2024-07-03 | 2024-07-01 | RGNX | KARABELAS ARGERIS N | Dir | M - OptEx | $0.00 | -10.0K | 30.0K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-01 | S | D | 10,000 | $11.27 | 11,286 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $10.98 to $11.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2024-07-01 | M | A | 10,000 | $3.76 | 21,286 | D | — | — | |
| 3 | Derivative | Stock Options (Right to Buy) | 2024-07-01 | M | D | 10,000 | $0.00 | 30,000 | D | $3.76 · — to 2025-05-18 | 10,000 Common Stock | (F3) The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter. |